Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company’s Phase 3 trials, its agreement with Tasly China and the near-term potential of stem cell medicines.
Most Popular
Southwest pilots say 737 MAX return may be delayed beyond Boeing’s fourth quarter goal
WASHINGTON (Reuters) - Southwest Airlines pilots predicted on Monday that the grounded Boeing 737 MAX airplane will return to the skies around February,...
Former US national security expert on Russia sits for deposition in impeachment inquiry
Former US national security expert on Russia sits for deposition in impeachment inquiry originally appeared on abcnews.go.comCongress continues closed-door depositions this week regarding...
ETH/USD attempts Bollinger Band upper breakout
Bollinger Band upper...
Operation Hope founder John Hope Bryant defends capitalism
John Hope Bryant, an advocate of economic empowerment through Operation Hope, wants Democratic presidential candidates Sens. Bernie Sanders, I-Vt., and Elizabeth Warren, D-Mass., to...
Earning season, bank earnings, manufacturing
Timothy A. Clary | Getty ImagesHere are the most important things to know about Tuesday before you hit the door.1. Bank earnings on...